Deposition of β-amyloid (Aβ) as senile plaques and disrupted glucose metabolism are two main characteristics of Alzheimer's disease (AD). It is unknown, however, how these two processes are related in AD. Here we examined the relationship between O-GlcNAcylation, which is a glucose level-dependent post-translational modification that adds O-linked β-N-acetylglucosamine (O-GlcNAc) to proteins, and Aβ production in a mouse model of AD carrying 5XFAD genes. We found that 1,2-dideoxy-2'-propyl-α- d-glucopyranoso-[2,1-d]-δ2'-thiazoline (NButGT), a specific inhibitor of O-GlcNAcase, reduces Aβ production by lowering γ-secretase activity both in vitro and in vivo. We also found that O-GlcNAcylation takes place at the S708 residue of nicastrin, which is a component of γ-secretase. Moreover, NButGT attenuated the accumulation of Aβ, neuroinflammation, and memory impairment in the 5XFAD mice. This is the first study to show the relationship between Aβ generation and O-GlcNAcylation in vivo. These results suggest that O-GlcNAcylation may be a suitable therapeutic target for the treatment of AD.
|Number of pages||11|
|Journal||Neurobiology of Aging|
|Publication status||Published - 2013 Jan|
Bibliographical noteFunding Information:
This work was supported by grants from NRF ( 2009-0081673 , 2008-05943 ), MRC ( 2011-0030738 ), WCU ( R32-10084 ); KNIH ROAD R&D Program Project ( A092058 ) for I. M-J. Also, grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology Grant ( 2011-0020479 ) and Korean Research WCU grant ( R31-10086 ) provided support to J.W.C.
All Science Journal Classification (ASJC) codes
- Clinical Neurology
- Developmental Biology
- Geriatrics and Gerontology